Cardiol Therapeutics Inc. (CRDL) News
Track canonical SquawkNews coverage tagged to CRDL, Cardiol Therapeutics Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 10 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Cardiol Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 03:02 PM UTC
L
HC Wainwright & Co. reiterates Buy rating on Cardiol Therapeutics, $9 price target
HC Wainwright & Co. reiterated their Buy rating on Cardiol Therapeutics's stock with a price target of $9.00.The price target implies an upside of 237.1% from the Sep 22 close of $2.67.Key takeaways from the analyst note
EQUITY | Sep 23, 2026, 02:53 PM UTC
L
CRDL - Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
CRDL - Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
NEWS | Sep 23, 2026, 10:06 AM UTC
H
Cardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent Pericarditis
As of September 23, 2026, 110 patients have been enrolled in MAVERIC, achieving the Company's original recruitment target ahead of its end-of-September guidance. "A blinded review of events in MAVERIC patients who have b
LIVE | Sep 23, 2026, 10:02 AM UTC
L
CRDL - Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
CRDL - Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
NEWS | Sep 16, 2026, 11:27 AM UTC
L
Cardiol Therapeutics files US$150M base shelf prospectus
REGULATION | Sep 10, 2026, 09:11 PM UTC
L
Cardiol Therapeutics files US$150m preliminary base shelf prospectus
Cardiol Therapeutics filed a preliminary base shelf prospectus for US$150 million, including additional disclosure following review by Ontario Securities Commission staff.
EQUITY | Sep 10, 2026, 09:00 PM UTC
L
Cardiol Therapeutics files shelf offering of up to $150 million
Cardiol Therapeutics Inc filed for a mixed shelf offering of up to $150 million.
EQUITY | Sep 10, 2026, 04:46 PM UTC
L
Cardiol Therapeutics to participate in fireside chat
Cardiol Therapeutics (CRDL) will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 09, 2026, 11:27 AM UTC
L
CRDL: Reports AGM Results
Cardiol Therapeutics reports results of 2026 Annual General Meeting of Shareholders
EARNINGS | Jun 25, 2026, 11:28 AM UTC